Endocrine Treatment-Related Symptoms and Patient Outcomes in Breast Cancer: A Meta-Analysis

YOO TAE KYUNG R; 장명진; 이은신; 문형곤; 노동영; 한원식

추천

검색

자료유형: 학술저널

저자정보: YOO TAE KYUNG R (가톨릭대학교) 장명진 (서울대학교) 이은신 (서울대학교병원) 문형곤 (서울대학교) 노동영 (서울대학교) 한원식 (서울대학교)

저널정보: 한국유방암학회 Journal of Breast Cancer Journal of Breast Cancer Vol.21 No.1

발행연도: 2018.1

수록면: 37 - 44 (8page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Purpose: An association between endocrine treatment-related symptoms and breast cancer recurrence has been suggested previously; however, conflicting results have been reported. We performed a meta-analysis of published studies to clarify this relationship. Methods: We systematically searched PubMed, Embase, Scopus, and the Cochrane database for studies investigating the association between endocrine treatment-related symptoms and patient survival. Random-effects meta-analysis was conducted with recurrence rate as the primary outcome. Results: Out of 7,713 retrieved articles, six studies were included. In patients who received endocrine treatment, the presence of any endocrine treatment-related symptom was found to be associated with a lower recurrence rate in comparison to an absence of any symptoms (hazard ratio [HR], 0.76; 95% confidence interval [CI], 0.66–0.87). This relationship persisted in patients presenting with only vasomotor or only musculoskeletal symptoms (HR, 0.74, 95% CI, 0.63–0.87; HR, 0.69, 95% CI, 0.55–0.86, respectively). At both time-points of symptom evaluation (3 months and 12 months), patients with endocrine treatment- related symptoms had a lower recurrence rate (HR, 0.74, 95% CI, 0.66–0.84; HR, 0.79, 95% CI, 0.69–0.90, respectively). This association was also significant in pooled studies including patients with and without baseline symptoms (HR, 0.73, 95% CI, 0.54–0.99; HR, 0.76, 95% CI, 0.69–0.85, respectively). Conclusion: Endocrine treatment-related symptoms are significantly predictive of lower recurrence rate in breast cancer patients, regardless of the type of symptoms, time-point of evaluation, or inclusion of baseline symptoms. These symptoms could be biomarkers for the prediction of long-term responses to endocrine treatment in patients with breast cancer.

참고문헌 (30)

참고문헌 신청

Ganz PA / 2016 / Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, doubleblind, phase 3 clinical trial / Lancet 387:857~865

Grunfeld EA / 2005 / Adherence beliefs among breast cancer patients taking tamoxifen / Patient Educ Couns 59:97~102

Ding K / 2008 / Validation of treatment induced specific adverse effect as a predictor of treatment benefit: a case study of NCIC CTG BR21 / Contemp Clin Trials 29:527~536

Zielinski C / 2016 / Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer / Br J Cancer 114:163~170

Mortimer JE / 2008 / Tamoxifen, hot flashes and recurrence in breast cancer / Breast Cancer Res Treat 108:421~426

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

YOO TAE KYUNG R

소속기관 Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea